stocks logo

ARQT

Arcutis Biotherapeutics Inc
$
14.860
-0.16(-1.065%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
15.2099
Open
14.940
VWAP
14.88
Vol
1.67M
Mkt Cap
1.77B
Low
14.440
Amount
24.87M
EV/EBITDA(TTM)
--
Total Shares
115.76M
EV
1.68B
EV/OCF(TTM)
--
P/S(TTM)
8.71
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. The ZORYVE is also indicated for topical treatment of mild to moderate atopic dermatitis. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. Its ARQ-255 is being developed for the treatment of alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
73.67M
+138.75%
-0.158
-62.3%
81.52M
+82.15%
-0.112
-66.16%
90.82M
+27.27%
-0.067
-25.92%
Estimates Revision
The market is revising Upward the revenue expectations for Arcutis Biotherapeutics, Inc. (ARQT) for FY2025, with the revenue forecasts being adjusted by 2.25% over the past three months. During the same period, the stock price has changed by 2.27%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2.25%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-2.13%
In Past 3 Month
Stock Price
Go Up
up Image
+2.27%
In Past 3 Month
7 Analyst Rating
up Image
43.27% Upside
Wall Street analysts forecast ARQT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARQT is 21.29 USD with a low forecast of 19.00 USD and a high forecast of 29.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy
up Image
43.27% Upside
Current: 14.860
sliders
Low
19.00
Averages
21.29
High
29.00
Goldman Sachs
Neutral
initiated
$18
2025-07-24
New
Reason
Goldman Sachs initiated coverage of Arcutis Biotherapeutics with a Neutral rating and $18 price target. The company's lead asset Zoryve has a favorable profile and is preferred by many dermatologists over generic topicals and steroids, but its growth going forward may be challenged, the analyst tells investors in a research note. The firm awaits clarity on Zoryve before recommending Arcutis shares.
Morgan Stanley
NULL
to
Overweight
upgrade
$19 -> $20
2025-07-03
Reason
Morgan Stanley assumed coverage of Arcutis Biotherapeutics with an Overweight rating and a price target of $20, up from $19. Arcutis is developing topical dermatology therapies and investor focus remains primarily on execution of the marketed Zoryve franchise and available follow-on indications, the analyst says. The firm estimates peak sales for Zoryve cream in plaque psoriasis and atopic dermatitis of $266M and $189M, respectively, and peak for Zoryve foam in seborrheic derm and scalp psoriasis of $267M and $77M.
Needham
Serge Belanger
Strong Buy
Reiterates
$20
2025-04-09
Reason
Needham
Serge Belanger
Strong Buy
Reiterates
$20
2025-04-03
Reason
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Reiterates
$19
2025-04-03
Reason
Guggenheim
Seamus Fernandez
Strong Buy
Reiterates
n/a
2025-04-03
Reason

Valuation Metrics

The current forward P/E ratio for Arcutis Biotherapeutics Inc (ARQT.O) is -38.43, compared to its 5-year average forward P/E of -7.10. For a more detailed relative valuation and DCF analysis to assess Arcutis Biotherapeutics Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.10
Current PE
-38.43
Overvalued PE
0.70
Undervalued PE
-14.89

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-5.75
Current EV/EBITDA
-31.53
Overvalued EV/EBITDA
0.76
Undervalued EV/EBITDA
-12.27

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
130.37
Current PS
5.31
Overvalued PS
348.49
Undervalued PS
-87.74

Financials

Annual
Quarterly
FY2025Q1
YoY :
+32.84%
65.85M
Total Revenue
FY2025Q1
YoY :
-22.43%
-24.53M
Operating Profit
FY2025Q1
YoY :
-29.17%
-25.06M
Net Income after Tax
FY2025Q1
YoY :
-37.50%
-0.20
EPS - Diluted
FY2025Q1
YoY :
-1.95%
-30.99M
Free Cash Flow
FY2025Q1
YoY :
-7.32%
86.59
Gross Profit Margin - %
FY2025Q1
YoY :
-46.68%
-38.06
Net Margin - %

Trading Trends

Insider
Insiders areSelling! The selling amount has increased 313.15% over the last month.
Sold
0-3
Months
1.3M
USD
11
3-6
Months
2.5M
USD
18
6-9
Months
1.8M
USD
12
0-12
Months
362.2K
USD
5
Bought
0-3
6
218.5K
USD
Months
3-6
0
0.0
USD
Months
6-9
3
34.0K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
482.2K
Volume
2
6-9
Months
1.5M
Volume
4
0-12
Months
0.0
Volume
0
Bought
0-3
1
22.5K
Volume
Months
3-6
2
1.5M
Volume
Months
6-9
4
955.9K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

ARQT News & Events

Events Timeline

2025-06-26 (ET)
2025-06-26
08:09:39
Arcutis announces ZORYVE cream receives strong recommendation from AAD
select
2025-06-10 (ET)
2025-06-10
08:14:24
Arcutis Biotherapeutics enrolls first child in INTEGUMENT-INFANT
select
2025-06-06 (ET)
2025-06-06
08:03:09
Arcutis Biotherapeutics presents new long-term results of ZORYVE cream
select
Sign Up For More Events

News

4.0
07-25Benzinga
This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
9.0
06-26Newsfilter
Arcutis' ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis
9.0
06-10Newsfilter
Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
Sign Up For More News

FAQ

arrow icon

What is Arcutis Biotherapeutics Inc (ARQT) stock price today?

The current price of ARQT is 14.86 USD — it has decreased -1.07 % in the last trading day.

arrow icon

What is Arcutis Biotherapeutics Inc (ARQT)'s business?

arrow icon

What is the price predicton of ARQT Stock?

arrow icon

What is Arcutis Biotherapeutics Inc (ARQT)'s revenue for the last quarter?

arrow icon

What is Arcutis Biotherapeutics Inc (ARQT)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Arcutis Biotherapeutics Inc (ARQT)'s fundamentals?

arrow icon

How many employees does Arcutis Biotherapeutics Inc (ARQT). have?

arrow icon

What is Arcutis Biotherapeutics Inc (ARQT) market cap?